Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700023421

Trial Profile

Clinical Trials Insight: 700023421

Phase of Trial: Phase I

Latest Information Update: 02 Mar 2010

At a glance

  • Drugs Tucidinostat (Primary)
  • Indications Cancer; Lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Chipscreen Biosciences; HUYA Bioscience International
  • Most Recent Events

    • 02 Mar 2010 Chipscreen aims to launch the drug in China by the end of 2010, according to a media release from the company.
    • 23 Oct 2008 Status changed from active, no longer recruiting to completed based on information provided in a HUYA Biosciences International media release.
    • 23 Oct 2008 Results have been reported in a HUYA Biosciences International media release; this data has also been presented at the Cambridge Healthtech Institute Fall Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top